ETBI — Eastgate Biotech Share Price
Last trade - 00:00- $5.74m
- $8.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 41.69 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -2882.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.13 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EastGate Biotech Corp. is a pharmaceutical company. The Company produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The Company utilizes nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. The Company’s products include E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze and Warts X. The Company also develops products in which the components are incorporated into vehicles containing nano-sized delivery vectors, including oil droplets (nanoemulsions), polymeric particles (nanoparticles) and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles).
Directors
- Last Annual
- December 31st, 2016
- Last Interim
- September 30th, 2017
- Incorporated
- September 8th, 1999
- Public Since
- January 16th, 2014
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 717,257,377
- Address
- 2203-65 Harbour Square, TORONTO, M5J 2L4
- Web
- https://eastgatebiotech.com/
- Phone
- +1 8013223401
- Auditors
- Sadler, Gibb & Associates, LLC
Similar to ETBI
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:07 UTC, shares in Eastgate Biotech are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Eastgate Biotech last closed at $0.01 and the price had moved by +247.83% over the past 365 days. In terms of relative price strength the Eastgate Biotech share price has outperformed the S&P500 Index by +199.01% over the past year.
There is no consensus recommendation for this security.
Eastgate Biotech does not currently pay a dividend.
Eastgate Biotech does not currently pay a dividend.
Eastgate Biotech does not currently pay a dividend.
To buy shares in Eastgate Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Eastgate Biotech had a market capitalisation of $5.74m.
Here are the trading details for Eastgate Biotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ETBI
Based on an overall assessment of its quality, value and momentum Eastgate Biotech is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eastgate Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +307.89%.
As of the last closing price of $0.01, shares in Eastgate Biotech were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eastgate Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eastgate Biotech's management team is headed by:
- Rose Perri - PRE
- Anna Gluskin - CEO
- Bill Abajian - COO